Bailey Montagu acknowledges Deloitte’s pharma R&D sector research

As an established search practice, with a major focus on life sciences, Bailey Montagu is interested to note the recent Deloitte research that shows estimated returns on investment in research and development (R&D) for 15 pharmaceutical companies worldwide have increased to 7.0 percent in 2021. It marks the highest level since 2014 when investments stood at 7.2 percent.

Deloitte’s research into the pharma R&D sector also found that the forecast average peak sales per asset stands at $521 million, markedly higher than the $422 million in 2020, and the highest level in four years. The growth, says Deloitte, is driven, in part, by the sales forecasts for emergency-approved Covid-19 treatments and vaccinations to the mass-market.

Andrew Linger, Partner Health & Life Sciences, commented on the study:

“The findings of this Deloitte research very much align with the active strategies coming out of our clients who are investing considerably.  They see the need to do so at this point to take advantage of forthcoming growth in demand and competition.

“We are continuing to see increasing hiring requirements at a senior level to support this growth and investment across our client base, and we are partnering these businesses with some interesting strategic, financial and operational requirements,” he added.